公开(公告)号：US12016926B2

公开(公告)日：2024-06-25

申请号：US16772273

申请日：2018-12-07

Applicant: BASF SE

Inventor： Ferdinand Paul Brandl ,  Theo Smit ,  Felicitas Guth ,  Karl Kolter ,  Maximilian Angel ,  Frank Schmidt

IPC: A61K9/16 ,  A61K31/216 ,  A61K31/5377 ,  A61K31/58 ,  A61K31/635 ,  A61K47/32 ,  C08F220/06 ,  C08F220/18 ,  C08F226/10

CPC classification number: A61K47/32 ,  A61K9/1635 ,  A61K31/216 ,  A61K31/5377 ,  A61K31/58 ,  A61K31/635 ,  C08F220/06 ,  C08F220/1803 ,  C08F220/1804 ,  C08F220/1806 ,  C08F226/10 ,  C08F220/1803 ,  C08F220/06 ,  C08F226/10 ,  C08F220/1806 ,  C08F220/06 ,  C08F226/10 ,  C08F220/1804 ,  C08F220/06 ,  C08F220/301

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

公开(公告)号：US20230272152A1

公开(公告)日：2023-08-31

申请号：US18029972

申请日：2021-10-05

Applicant: BASF SE

Inventor： Ferdinand Paul Brandl ,  Theo Smit ,  Karl Kolter ,  Felicitas Guth ,  Karl Haeberle ,  Frederic Lucas

IPC: C08G18/34 ,  C08G18/12 ,  A61K9/16 ,  C08G18/32

CPC classification number: C08G18/348 ,  A61K9/1641 ,  C08G18/12 ,  C08G18/3206 ,  C08G18/3212 ,  C08G18/3218

Abstract: The present invention relates to novel polyurethanes based on a diisocyanate, a carboxylic acid functionalized diol and an acid-free diol, their use as pharmaceutical excipients for improving gastrointestinal absorption, the respective pharmaceutical dosage forms and methods for making the polyurethanes.

公开(公告)号：US11723871B2

公开(公告)日：2023-08-15

申请号：US17052934

申请日：2019-05-15

Applicant: BASF SE

Inventor： Theo Smit ,  Matthias Karl ,  Felicitas Guth ,  Maximilian Angel ,  Karl Kolter ,  Frank Schmidt ,  Maximilian Blochberger-Claus

IPC: A61K9/20

CPC classification number: A61K9/2027 ,  A61K9/2031

Abstract: The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms.

公开(公告)号：US20180353875A1

公开(公告)日：2018-12-13

申请号：US16060043

申请日：2016-12-12

Applicant: BASF SE

Inventor： Pedro Sa Gomes ,  Bastiaan Bram Pieter Staal ,  Felicitas Guth ,  Nigel A. Langley

IPC: B01D15/34 ,  B01D15/18 ,  C08G65/30 ,  C08G65/08

CPC classification number: B01D15/34 ,  B01D15/1807 ,  B01D15/1821 ,  B01D15/1871 ,  B01D15/1892 ,  C08G65/08 ,  C08G65/30 ,  C08G2650/58

Abstract: A process for purification of polyether block copolymers comprising polyoxyethylene and polyoxypropylene moieties using sequential multi-column size exclusion chromatography apparatus operated as a counter current moving bed wherein a process cycle comprises the steps of.

公开(公告)号：US20180235885A1

公开(公告)日：2018-08-23

申请号：US15753186

申请日：2016-08-17

Applicant: BASF SE

Inventor： Heiko Alexander Schiffter ,  Maximilian Angel ,  Karl Kolter ,  Felicitas Guth

IPC: A61K9/16 ,  A61K47/69 ,  A61K9/20 ,  C08L39/06 ,  C08L33/08

CPC classification number: A61K9/1635 ,  A61K9/2027 ,  A61K31/00 ,  A61K31/426 ,  A61K31/451 ,  A61K31/4515 ,  A61K31/495 ,  A61K47/6933 ,  C08F220/06 ,  C08F220/18 ,  C08F226/10 ,  C08L33/08 ,  C08L39/06 ,  C08L2203/02

Abstract: Water-soluble polymeric salts of medicaments sparingly soluble in water consisting of a cationogenic medicament which, in uncharged form or as hydrochloride, has a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice, and an anionogenic water-soluble polymer having a solubility in water of at least 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight.

公开(公告)号：US20180228730A1

公开(公告)日：2018-08-16

申请号：US15751889

申请日：2016-08-17

Applicant: BASF SE

Inventor： Heiko Alexander Schiffter ,  Maximilian Angel ,  Karl Kolter ,  Felicitas Guth

IPC: A61K9/16 ,  A61K9/14 ,  A61K9/48 ,  A61K31/4515

Abstract: Use of a water-soluble polymer having a solubility in water of greater than 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight, for the formulation of basic active ingredients sparingly soluble in water, wherein the active ingredients in uncharged form or as hydrochloride have a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice.

公开(公告)号：US09789063B2

公开(公告)日：2017-10-17

申请号：US14036365

申请日：2013-09-25

Applicant: BASF SE

Inventor： Felicitas Guth ,  Karl Kolter ,  Michael Schönherr ,  Michael Klemens Müller

IPC: A61K9/00 ,  A61K47/00 ,  A61K9/16 ,  A61K47/22 ,  A61K47/32

CPC classification number: A61K9/1617 ,  A61K9/1682 ,  A61K47/22 ,  A61K47/32

Abstract: Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 μm is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.

公开(公告)号：US20140086992A1

公开(公告)日：2014-03-27

申请号：US14036365

申请日：2013-09-25

Applicant: BASF SE

Inventor： Felicitas Guth ,  Karl Kolter ,  Michael Schönherr ,  Michael Klemens Müller

IPC: A61K9/16

CPC classification number: A61K9/1617 ,  A61K9/1682 ,  A61K47/22 ,  A61K47/32

Abstract: Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 μm is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.

Abstract translation: 描述了储存稳定的无尘均匀颗粒制剂。 该制剂包含（a）至少一种水溶性维生素E衍生物，（b）至少一种亲水性聚合物，（c）任选地附加的表面活性物质，和（d）任选的另外的药物添加剂。 （a），（b），（c）和（d）的总和等于制剂重量的100％。 粒径小于100μm的细小部分小于10重量％。 还描述了制备制剂的方法，以及在药物制剂中使用该制剂作为增溶组合物。